Vascular Effects of SGLT2i in Non-diabetic CKD

Conditions

• Non-diabetic Chronic Kidney Disease

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Empagliflozin — DRUG
  Empagliflozin 10 mg, encapsulated to match the placebo, will be used.
• Placebo — DRUG
  Matching placebo will be used.

Study Details

Empagliflozin, a sodium-glucose co-transporter 2 inhibitor (SGLT2i), is a novel diabetic medication that reduces the risk of progression of chronic kidney disease (CKD) and heart failure and improves exercise tolerance regardless of the diabetes status. One of the important ways that empagliflozin improves health may be through its benefits on blood vessels. The effects of empagliflozin on blood vessels and physical function have not been examined in patients with chronic kidney disease, and it is less clear if empagliflozin may be beneficial in patients with chronic kidney disease without heavy urinary protein leakage. The investigators will examine if empagliflozin can improve blood vessel function and exercise tolerance in Veterans with chronic kidney disease without heavy urinary protein leakage.

Key Dates

Start date

Aug 1, 2026

Status verified

May 2026

Primary completion

Mar 31, 2029

Completion

Sep 30, 2029

Study Design

Enrollment

52 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Placebo Comparator: Placebo
  The placebo will be encapsulated to look identical to the study drug.
• Other: Empagliflozin
  Matching 10-mg empagliflozin dose will be used.

Primary Outcome Measure

Change in endothelium-dependent vasodilation as measured by flow mediated dilation (FMD) [ Time Frame: baseline, 8 weeks, 16 weeks ]

Central Contacts

• Monique Cho, MD
  (801) 582-1565
  [email protected]

Locations (1)

Find similar trials in Salt Lake City, UT